Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450320 · ClinicalTrials.gov registry record · Phase 1
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00450320 is a Phase 1 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 7 participants.
The verdict
NCT00450320, a Phase 1 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sirolimus also may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This pilot study is studying sirolimus in treating patients with HIV-related Kaposi's sarcoma.
Interventions
- DRUG sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450320
The ClinicalTrials.gov registry entry for NCT00450320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sirolimus is the first listed.
NCT00450320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450320 about?
NCT00450320 is a clinical study titled "Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma". RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sirolimus also may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking ...
What is the current status of trial NCT00450320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2007-10. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00450320?
The interventions under investigation include: sirolimus (DRUG).
Who is sponsoring clinical trial NCT00450320?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.